Objectives: To investigate the impact of anemia on 2-year outcomes in patients undergoing contemporary percutaneous coronary intervention (PCI).
Previous studies consistently demonstrated that anemic patients underwent PCI were associated with significantly higher mortality and major adverse cardiovascular events (MACE) than non-anemic patients. [1] [2] [3] [4] [5] [6] [10] [11] [12] However, as several studies had suggested that anemia was no longer associated with increased mortality after adjustment for potential confounders, 6, 13, 14 whether anemia was an independent predictor of adverse outcomes after PCI, that is, outcomes were driven by anemia per se or by higher baseline risks, was under debate. 15 Furthermore, some studies indicated that anemia was only associated with poorer outcomes in patients with severe anemia but not in those with mild or moderate anemia, 6, 10 and some studies suggested that it was post procedural anemia that was independently associated with MACE. 7, 11 In addition, the prevalence of anemia and how anemia affected the prognosis in Chinese patients undergoing PCI was scarcely reported before. 12 Therefore, we carried out this large sample study in a large Chinese cardiovascular center, to investigate the impact of anemia on 2-year clinical outcomes in
Chinese patients undergoing contemporary PCI treatment. and <120 g/L for women. 16 Pre-PCI anemia was determined according to serum hemoglobin value examined at admission, while post-PCI anemia was determined according to nadir serum hemoglobin value examined within 24 h after PCI.
| Procedure details
The PCI strategy, drugs, or devices used during the procedure were at the physician's discretion. The peri-procedure antiplatelet and anticoagulant therapy were administered on the basis of current practice recommendations. After the procedure, aspirin was prescribed at a dose of 100 mg daily indefinitely; clopidogrel 75 mg daily or ticagrelor 90 mg twice daily was advised for at least 1 year after PCI.
New generation drug-eluting stent was defined as second generation and polymer-free drug-eluting stent.
| Follow-up
All patients were evaluated by clinic visit or by phone at 1, 3, 6, and 12 months and annually thereafter. The endpoints assessed in this study included 2-year all-cause death, myocardial infarction (MI), repeat revascularization, target-vessel revascularization (TVR), bleeding, stroke, and major adverse cardiovascular events (MACE, composite of all-cause death, MI, and repeat revascularization). Myocardial Infarction (MI) was defined according to the third universal definition of myocardial infarction. 17 Target vessel revascularization (TVR) was defined as any revascularization procedure, either percutaneous or surgical, involving the target vessel.
Bleeding was quantified according to Bleeding Academic Research
Consortium Definition criteria, 18 including type 1-5 in the analysis. All endpoints were adjudicated centrally by two independent cardiologists, and disagreement was resolved by consensus. to assemble a paired cohort of patients with or without anemia with similar baseline characteristics. Nearest neighbor matching with a 1:1 ratio (caliper value: 0.1) was applied. In the propensity score-matched population, the survival curves were estimated using the Kaplan-Meier plots and compared using the log-rank tests. A COX proportional hazards model which included the same covariables mentioned above was also performed. In addition, hazard ratios (HRs) were calculated with a stratified model according to the hemoglobin level. The patients were stratified into groups at 10 g/L intervals. The intervals with the most patients were reference intervals. The HRs for the effect of hemoglobin levels were calculated using fully adjusted COX proportional hazards models. Results are reported as HR with associated 95% confidence interval (CI) and P values. The P value <0.05 was considered significant.
| Statistical analyses
Propensity score matching was performed with the R statistical software (www.r-project.org). All of the other statistical analyses were performed with SPSS 22.0 (IBM Corp., Armonk, NY).
3 | RESULTS
| Baseline characteristics
Within this study population of 10 717 patients, 1348 (12.5%) and 3111 (29.0%) patients presented with pre-and post-PCI anemia according to WHO criteria, respectively. The mean pre-and post-PCI hemoglobin were shown in Table 1 , it was notable that patients with post-PCI anemia had a more significant hemoglobin decrease after PCI (13.6 ± 11.8 g/L)
than that in patients with pre-PCI anemia (1.9 ± 9.8 g/L).
Baseline characteristics are presented in Table 1 . Patients with pre-PCI anemia were older, more often female, more often presented with acute coronary syndrome and had more co-morbidities including hypertension, diabetes, cerebral vascular disease and peripheral arterial disease, more previous coronary artery bypass grafting, and lower estimated glomerular filtration rate than patients without pre-PCI anemia.
Coronary disease at baseline was significantly more extensive and more complex in patients with pre-PCI anemia, who had higher baseline Synergy Between PCI With Taxus and Cardiac Surgery (SYNTAX) Score and more type B2/C lesions, resulting in higher rate of PCI through femoral artery pathway. However, procedure success rates were equally high in both groups (pre-PCI anemia: 97.6% vs non-pre-PCI anemia: Covariables adjusted included age, sex, BMI, current smoker, hypertension, diabetes, hyperlipidemia, prior MI, prior PCI, prior CABG, CVD, PVD, pre-PCI SYNTAX score, LVEF < 40%,GFR < 60, three-vessel disease, left main disease, B2/C lesions, ACS.
97.9%, P = 0.43). Patients with post-PCI anemia were also in higher clinical risks just as patients with pre-PCI anemia (Table 1) .
| Clinical outcomes
Two-year follow-up was completed for 10 658 patients (99.4%). The rates of adverse cardiovascular events in each group was shown in Figure 1 . The rates of bleeding (8.4% vs 6.3%, P = 0.003) and stroke (1.9% vs 1.3%, P = 0.05) were significantly higher in patients with pre-PCI anemia than those without pre-PCI anemia, while the rates of all-cause death, myocardial infarction (MI), repeat revascularization, and major adverse cardiovascular events (MACE) were not significantly different between the two groups. When comparing patient with post-PCI anemia versus those without post-PCI anemia, the rates of all-cause death (1.6% vs 1.0%, P = 0.01), MI (2.8% vs 1.6%, P < 0.001), target vessel revascularization (TVR) (6.3% vs 4.9%, P = 0.002), bleeding (8.3% vs 5.8%, P < 0.001) and MACE (12.4% vs 10.3%, P = 0.001) were all significant higher in post-PCI anemia group. After multivariable-adjusted analysis, pre-PCI anemia was not an independent risk factor of any clinical adverse events (all P > 0.05) ( Table 2) , and post-PCI anemia was not an independent risk factor of allcause death either (P > 0.05), although it was an independent risk factor of MI, TVR, bleeding, and MACE (all P < 0.05) ( Table 3 ).
| Propensity score matched analyses
After propensity score matching, all baseline characteristics were balanced between patients with and without pre-PCI anemia, as well as between patients with and without post-PCI anemia (all P > 0.05) (Supplemental Table S1 ). Through multivariable-adjusted analysis in the propensity score matched groups, we finally found that pre-PCI anemia was not an independent risk factor of any endpoints, while post-PCI anemia was still an independent risk factor of MI, TVR, and MACE (all P < 0.05) ( Table 3 ).
| Stratified model
After further analysis of the data using a stratified model based on g/L of hemoglobin, there appeared to be an association of reduced hemoglobin levels with 2-year mortality (Figure 2) , the threshold value of increased mortality was less than 100 g/L for both pre-PCI anemia (HR 3.72, 95% CI 1.22-11.36, P = 0.02) and post-PCI anemia (HR 2.99, 95%CI 1.45-6.17, P = 0.003). In addition, the graphs indicated a trend that mortality also appeared to be higher at the upper extremes of hemoglobin level (>170 g/L) compared with the comparatively normal range.
| Subgroup analysis
We also conducted the subgroup analyses stratified by the status of acute coronary syndrome (ACS). The ACS group (n = 6425) included patients admitted to hospital because of unstable angina pectoris or acute myocardial infarction. The non-ACS group (n = 4292) included patients with stable angina pectoris or silent ischemia. In patients with stable coronary disease (non-ACS group), pre-PCI anemia was not an independent risk factor of any clinical adverse events. Post-PCI anemia was not an independent risk factor of all-cause death or MACE, but it was an independent risk factor of bleeding (Supplemental Table S1 ). In patients with ACS, pre-PCI anemia was not an independent risk factor of any clinical adverse events. Post-PCI anemia was not an independent risk factor of all-cause death or MACE, but was an independent risk factor of MI and bleeding (Supplemental Table S2 ).
| DISCUSSION
In this study, the impact of anemia on clinical outcomes after PCI was assessed in a large cohort of real-world patients in a big Chinese cardiovascular center. The major findings of this study were as follows: 1) in the consecutive Chinese patients undergoing PCI in 2013, the prevalence of anemia were 12.5% and 29.0% pre-and post-PCI, respectively; 2) anemic patients were in higher baseline clinical risks, and had worse clinical outcomes during 2-year follow-up after PCI; 3) after multivariable-adjusted analysis, pre-PCI anemia was not an independent risk factor of any clinical adverse events, but post-PCI anemia still had a predictable value of myocardial infarction (MI), target vessel revascularization (TVR) and major adverse cardiovascular events (MACE) after PCI; and 4) the threshold value of increased risk of mortality was less than 100 g/L for both pre-PCI anemia and post-PCI anemia.
FIGURE 2
Adjusted hazard ratios for mortality at hemoglobin increments of 10 g/L before PCI (A) and after PCI (B). PCI, percutaneous coronary intervention Numerous studies reported the prevalence of anemia in patients undergoing PCI, which varied from 10% to >30% in different clinical settings. [1] [2] [3] [4] [5] [6] [7] But, what prevalence of anemia in Chinese patients underwent PCI was scarcely reported before. In this study of 10 717
consecutive Chinese patients undergoing PCI in our center in 2013, the prevalence of anemia was 12.5% and 29.0% pre-and post-PCI, respectively, which were comparable to other similar studies. 4, 7 This study demonstrated that patients with anemia were in significantly higher baseline clinical risks than patients without anemia, including advanced age, acute coronary syndrome, diabetes, renal insufficiency, and extensive coronary disease, which also were shown by previous studies. [1] [2] [3] [4] [5] [6] [10] [11] [12] So, it was predictable that these anemic patients had worse clinical outcomes. In this study, patients with pre-PCI anemia experienced higher incidence of bleeding and stroke, and patients with post-PCI anemia had higher the rates of all-cause death, myocardial infarction (MI), target vessel revascularization (TVR), bleeding, and major adverse cardiovascular events (MACE) during 2-year follow-up. This phenomenon that anemic patients had worse prognosis after PCI was almost exclusively observed by previous studies. [1] [2] [3] [4] [5] [6] [10] [11] [12] However, anemia was only a marker of baseline clinical risks resulting in worse prognosis after PCI, or anemia per se was an independent predictor of adverse outcomes after PCI, needed to be clarified, because the detrimental effects of anemia on the cardiovascular system have been well described: 1) anemia can result in myocardial ischemia especially under states with higher metabolic demands such as exertion, and can particularly compound the already jeopardized oxygenation of the myocardium during acute coronary syndrome 19 ;
2) for anemic patients undergoing PCI, dual anti-platelet therapy can unmask or exacerbate underlying processes such as occult gastrointestinal bleeding and bleeding diatheses, and premature discontinuation of dual anti-platelet therapy secondary to bleeding, which, particularly after implantation of drug-eluting stent, is associated with higher incidence of stent thrombosis 4, 20 ; and 3) anemia may be associated with presence of more vulnerable coronary plaques as evidenced by a higher burden of necrotic core and thin-cap fibroatheroma. 21 Previous studies reported conflicting data regarding the association between anemia and clinical outcomes in patients undergoing PCI. Some studies reported both an independent association with increased mortality, major adverse cardiovascular events (MACE), and major bleeding complications [1] [2] [3] [4] [5] [10] [11] [12] while other studies reported no increase in risk after adjustment for differences in age, co-morbidity burden and procedural demographics. 6, 13, 14 In this study of a large cohort of PCI patients, we performed rigorous statistical analysis with a COX proportional hazards model in the propensity score-matched population to minimize the influence of other confounders on clinical outcomes. We found that pre-PCI anemia was not an independent risk factor of any clinical adverse events, indicating that pre-PCI anemia may merely be a marker of a greater co-morbid in frailer patients. On the contrary, we found that post-PCI anemia was an independent risk factor of myocardial infarction (MI), target vessel revascularization (TVR) and MACE after multivariable-adjusted analysis. But, it was notable that patients with post-PCI anemia had a significant hemoglobin decrease after PCI, indicating more bleeding events occurred in patients with post-PCI anemia. As the significant adverse effects of bleeding on outcomes in patients undergoing PCI, particularly if blood transfusions become necessary, have been firmly established, [22] [23] [24] it was comprehensible that post-PCI anemia was more likely to have prognostic value than pre-PCI anemia. 7, 11 In addition, since the relationship between hemoglobin level and risk is not linear, 25 the complexity of this interaction cannot be appreciated using a single hemoglobin cutoff value (such as the World Health Organization definition). In this study, we found that the threshold value of increased mortality was less than 100 g/L for both pre-PCI and post-PCI anemia. This finding, in line with some previous studies, 6, 10 implied that anemia was only associated with poorer outcomes in patients with severe anemia but not mild or moderate anemia. Furthermore, we observed a trend of an increased mortality in patients in a higher range of hemoglobin level (170 g/L). So, analyzing patients using a single cutoff value will potentially underestimate the risk of low hemoglobin levels because of the possible effects of the elevated risk in the patients with high hemoglobin levels.
Several limitations have to be taken into consideration. The major limitation of this study was its observational non-randomized design, which introduced latent, unrecognized, or unmeasured variables that resulted in hidden bias despite although we had performed rigorous statistical analysis with a COX proportional hazards model in the propensity score-matched population to reduce selection bias. In addition, it was unclear whether these results applied for longer follow-up durations, considering that adverse outcomes in anemic patients tended to aggregate over time. Furthermore, patients' hemoglobin levels at follow-up was not clear, since prior study demonstrated that patients whose anemia normalized over time did not seem to have an excess mortality risk. 26 
| CONCLUSION
In this large cohort of real-world Chinese patients who underwent modern PCI, anemic patients were in higher baseline clinical risks and had worse prognosis during 2-year follow-up. However, after multivariate analysis, pre-PCI anemia was not an independent risk factor of any clinical adverse events, but post-PCI anemia was still an independent risk factor of myocardial infarction (MI), target vessel revascularization (TVR), and major adverse cardiovascular events (MACE). There appeared to be a threshold value of 100 g/L hemoglobin associated with increased mortality, which warrants further investigation. Hospital for their research contributions. We also appreciate the help from information center for providing some of the data.
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